Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) FCF Margin (2016 - 2025)

Cardiff Oncology's FCF Margin history spans 15 years, with the latest figure at 2743.62% for Q4 2025.

  • For Q4 2025, FCF Margin rose 400274.0% year-over-year to 2743.62%; the TTM value through Dec 2025 reached 6520.57%, down 100990.0%, while the annual FY2025 figure was 6520.57%, 100183.0% down from the prior year.
  • FCF Margin for Q4 2025 was 2743.62% at Cardiff Oncology, up from 9060.0% in the prior quarter.
  • Across five years, FCF Margin topped out at 2743.62% in Q4 2025 and bottomed at 13886.49% in Q1 2022.
  • The 5-year median for FCF Margin is 6537.51% (2021), against an average of 7213.1%.
  • The largest annual shift saw FCF Margin surged 677814bps in 2024 before it plummeted -875050bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 5710.53% in 2021, then dropped by -28bps to 7317.97% in 2022, then skyrocketed by 37bps to 4581.41% in 2023, then crashed by -47bps to 6746.36% in 2024, then skyrocketed by 59bps to 2743.62% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's FCF Margin are 2743.62% (Q4 2025), 9060.0% (Q3 2025), and 6142.15% (Q2 2025).